Table 2.

Relative risks of second relapse, treatment failure, and overall mortality

	Early relapse (<36 mo)			Late relapse (≥36 mo)
Outcome	N1/N2	RR (95% CI)	P	N1/N2	RR (95% CI)	P
Leukemia recurrence
Chemotherapy	76/110	1.00	< .001*	23/78	1.00	< .001*
TBI regimen	41/92	0.49 (0.33-0.71)	< .001	16/61	0.92 (0.49-1.70)	.78
Non-TBI regimen	15/19	1.33 (0.78-2.25)	.29	4/14	2.49 (1.21-5.10)	.01
Treatment failure
Chemotherapy	85/110	1.00	< .001*	32/78	1.00	< .001*
TBI regimen	50/92	0.55 (0.39-0.79)	< .001	24/61	1.10 (0.66-1.84)	.70
Non-TBI regimen	17/19	1.56 (0.92-2.48)	.06	9/14	3.11 (1.72-5.62)	< .001
Overall mortality
Chemotherapy	77/110	1.00	< .001*	26/78	1.00	< .001*
TBI regimen	48/92	0.58 (0.41-0.83)	.003	22/61	1.21 (0.70-2.07)	.49
Non-TBI regimen	15/19	1.51 (0.94-2.43)	.09	9/14	3.14 (1.68-5.85)	< .001

N1 indicates number of events; N2, number evaluable.

^*Two-degree freedom test.